In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $39.07 down -2.47% from its previous closing price of $40.06. In other words, the price has decreased by -$2.47 from its previous closing price. On the day, 1.69 million shares were traded. IONS stock price reached its highest trading level at $40.01 during the session, while it also had its lowest trading level at $39.0.
Ratios:
For a deeper understanding of Ionis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.51 and its Current Ratio is at 7.61. In the meantime, Its Debt-to-Equity ratio is 7.50 whereas as Long-Term Debt/Eq ratio is at 7.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on August 02, 2024, Downgraded its rating to Market Perform and sets its target price to $60 from $67 previously.
On July 24, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $53 to $62.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 29 ’24 when Geary Richard S sold 331 shares for $49.63 per share. The transaction valued at 16,428 led to the insider holds 84,823 shares of the business.
Geary Richard S sold 320 shares of IONS for $15,731 on Aug 28 ’24. The EVP, Chief Development Officer now owns 85,154 shares after completing the transaction at $49.16 per share. On Aug 05 ’24, another insider, Geary Richard S, who serves as the EVP, Chief Development Officer of the company, sold 2,430 shares for $48.00 each. As a result, the insider received 116,640 and left with 85,508 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 6161768960 and an Enterprise Value of 5612715520. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.57 while its Price-to-Book (P/B) ratio in mrq is 21.64. Its current Enterprise Value per Revenue stands at 6.9 whereas that against EBITDA is -16.974.
Stock Price History:
Over the past 52 weeks, IONS has reached a high of $54.44, while it has fallen to a 52-week low of $35.95. The 50-Day Moving Average of the stock is -15.65%, while the 200-Day Moving Average is calculated to be -13.85%.
Shares Statistics:
For the past three months, IONS has traded an average of 1.56M shares per day and 1843260 over the past ten days. A total of 157.71M shares are outstanding, with a floating share count of 144.60M. Insiders hold about 8.31% of the company’s shares, while institutions hold 90.05% stake in the company. Shares short for IONS as of 1726185600 were 10614257 with a Short Ratio of 6.80, compared to 1723680000 on 9902786. Therefore, it implies a Short% of Shares Outstanding of 10614257 and a Short% of Float of 7.8600004000000006.
